世界の医薬品原薬（API)市場は、2020年の1,880億ドルから2030年までに3,360億ドルに達し、今後数年間、つまり2021〜30年のCAGRは6.23％と予想されます。市場の成長を促す要因としては、慢性疾患の有病率の上昇、API製造技術の進歩、ジェネリック医薬品の採用の増加、個別化医療への関心の高まり、および医薬品セクターへの投資の増加などが挙げられます。
医薬品原薬（API）は、医薬品の製造に使用される化学物質です。すべての医薬品は、医薬品有効成分（API）と賦形剤の2つの部分で構成されています。賦形剤は、APIの担体として機能する薬物の不活性成分です。たとえば、パラセタモールはAPIであり、結合剤（デンプンなど）はパラセタモール錠剤の賦形剤です。FDAによると、APIは診断、治癒、緩和、治療、または病気の予防のための薬理学的活動またはその他の直接的な効果を根付かせるために使用されます。
目次
Contents
1. Executive Summary
2. Global Active Pharmaceutical Ingredient Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Active Pharmaceutical Ingredient Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Active Pharmaceutical Ingredient Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Billion Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global Active Pharmaceutical Ingredient Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Type: Market Share (2020-2030F)
12.2.1. Innovative, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Generic, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Communicable Diseases, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Oncology, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Cardiovascular Diseases, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Diabetes, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Pain Management, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Chronic Respiratory Diseases, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.7. Other, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Type of Synthesis: Market Share (2020-2030F)
12.4.1. Synthetic, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Biotech, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
Company Profile
1. Cipla
1. Company Overview
2. Company Total Revenue (Financials)
3. Market Potential
4. Global Presence
5. Key Performance Indicators
6. SWOT Analysis
7. Product Launch
2. Bristol Myers Squibb
3. Boehringer Ingelheim GmbH
4. BASF SE
5. Aurobindo Pharma
6. Albemarle Corporation
7. Abbvie Inc.
8. Dr. Reddy’s Laboratories Ltd
9. Eli Lilly and Company
10. Viatris Inc.
11. Other Prominent Players
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
